School of Optometry 眼科視光學院
Home About Us What's New Subscribe eNewsletter Contact Us My School 繁體 简体 Text Only Print
About us
Message from Head of School
Vision & Mission
Our People
Academic Staff
Affiliate Faculty Members
Honorary & Adjunct Professor
Visiting Staff & Academic Visitors
Optometry Clinic Staff
Research Staff
Research Students
Our Research
About us > Our People > Research Students > Mr. Chunghim SO
Our People
Mr. Chunghim SO | Mr. Dong LIANG | Mr. Milan RAI | Ms. Jing ZHANG | Ms. Shuwen JIA | Ms. Wing Yan LAU | Ms. Yingkun CUI | Ms Jingfang Jennifer BIAN | Mr Shashi Kant CHAUDHARY | Ms Meng CHENG | Mr Ka Wai Jimmy CHEUNG | Ms Hang I Christie LAM | Ms Hoi Lam LI | Ms Sonal Aswin VYAS | Mr Kin Ken WAN | Ms Biyue GUO | Ms Li PAN | Ms Qi TAN | Mr Mezbah UDDIN | Ms Rong LI | Ms. Yuanyuan LIANG | Ms Anqi LYU | Mr Ying Hon SZE | Ms Qin WANG | Ms Hanyu ZHANG | Ms Wei YANG | Ms Mei ZHAO | Ms Yajing YANG | Ms Fangyu XU | Mr Sung Hei Jimmy TSE | Ms. Seen Hang CHAN | Mr. CHAN Kin Ho | Ms. AYERAKWAH Patience Ansomah | Mr. SO Ching | Mr. CATRAL Kirk Patrick Carreon | Mr. LIU Zhengji | Mr. LU Daqian | Ms. QIU Chunting | Mr. YANG Xiayin

Mr. Chunghim SO

Mr. Chunghim SO
PhD Student

ORCiD 0000-0002-7439-5741

Title of project:
Effect of NSAID in treating non-proliferative diabetic retinopathy in STZ-induced mice

Diabetic retinopathy (DR), a diabetes complication related to the eyes, is a medical condition in which retinal damage occurs and could progress to blindness at the late stage. One of the most common features of non-proliferative diabetic retinopathy (NPDR) is capillary occlusion. During occlusion, ischemia and hypoxia could drive the microenvironment into a pro-inflammatory state. Using a mice model of type 1 diabetic induced streptozotozin, this study attempts to administer the tested drugs such as aspirin directly into the eye through intravitreal injection in order to prevent the progression of DR. In addition, visual optokinetic response and intracellular labelling will be used to determine the efficacy of the treatment by observing visual acuity and alpha ganglion cell morphology, respectively. The long-term goal is to develop a new line of drug to benefit patients with diabetic retinopathy.